Negative in Ames, in vitro CHO chromosome aberration and in vivo rat micronucleus assays
“Fruquintinib was not mutagenic in the in vitro bacterial reverse mutation assay or clastogenic in the in vitro chromosomal aberration assay in Chinese hamster ovary (CHO) cells. The in vivo bone marrow micronucleus assay in rats was negative.”
✓ VerifiedFDA multi-discipline review, p. 34Source ↗
Carcinogenicity
Not conducted (advanced cancer indication, ICH S9)
“Carcinogenicity studies were not performed and are not required for pharmaceuticals intended for the treatment of advanced cancer (ICH S9).”
Rat EFD: teratogenicity and embryo lethality at exposures below clinical exposure
“In an embryo-fetal developmental study in pregnant rats, oral administration of fruquintinib during the period of organogenesis resulted in teratogenicity and embryo lethality at exposures below the clinical exposure (see Data ) .”
No significant cardiovascular or respiratory effects in dogs or neurobehavioral effects in rodents
“Fruquintinib did not have a toxicologically significant effect on cardiovascular or respiratory function in dogs or neurobehavioral function in rats.”
✓ VerifiedFDA multi-discipline review, p. 32Source ↗
Not genotoxic overall: Ames negative; in vitro chromosome aberration positive without (not with) metabolic activation; rat micronucleus and comet negative